Business Overview: Relay Therapeutics, Inc. (NASDAQ: RLAY)

---

Executive Summary

Relay Therapeutics is a clinical-stage precision oncology (and broader precision medicine) biotechnology company built around its proprietary Dynamo computational and biophysical drug discovery platform, which models protein motion to design small-molecule therapies targeting previously "undruggable" or difficult-to-target disease mechanisms. Its lead program, RLY-2608, is a mutant-selective PI3K-alpha inhibitor in clinical development for PIK3CA-mutated breast cancer.

Relay matters as a platform biotechnology company whose value proposition rests on the differentiation of its drug discovery technology itself, rather than on any currently approved, revenue-generating product — making it a higher-risk, pipeline-dependent business whose success depends on clinical trial outcomes and eventual regulatory approval.

---

1. Core Business Model & How They Work

Dynamo computational/biophysical drug discovery platform
        ⬇️
Design small molecules targeting protein motion-based mechanisms
        ⬇️
Advance candidates through clinical trials (lead: RLY-2608 in PIK3CA-mutated breast cancer)
        ⬇️
Revenue (future): product sales or partnership/licensing deals upon successful development

As a clinical-stage company, Relay currently generates little to no product revenue; its economics depend on successfully advancing pipeline candidates through trials, potential partnership/collaboration deals, and eventual regulatory approval and commercialization.

---

2. Business Segments

Relay operates as a single clinical-stage biopharmaceutical research and development business; it does not report distinct operating segments.

---

3. Product Portfolio

---

4. Competitive Landscape

Relay competes with other companies developing PI3K pathway inhibitors and precision oncology therapies, including larger pharmaceutical companies with approved PI3K inhibitors (such as Novartis's Piqray/alpelisib) and other biotechs developing next-generation, more selective PI3K-targeting agents. Relay's differentiation claim rests on RLY-2608's mutant-selectivity, designed to reduce the hyperglycemia and other wild-type PI3K-related toxicities that have limited broader use of earlier PI3K inhibitors.

---

5. Strategic Strengths & Risks

Strengths:

• Differentiated computational drug discovery platform (Dynamo) that models protein dynamics, potentially enabling access to difficult-to-drug targets.
• Mutant-selective design approach for RLY-2608 directly addresses a known tolerability limitation of earlier-generation PI3K inhibitors.
• Pipeline optionality beyond the lead program, if the platform can be validated across multiple target classes.

Risks:

• No approved products or product revenue — Relay's value is entirely dependent on clinical trial success and eventual regulatory approval.
• Binary clinical trial risk typical of clinical-stage biotech, where a single trial failure can sharply impair the company's prospects.
• Capital intensity and cash runway risk, requiring continued capital markets access or partnership deals to fund development through to commercialization.

---

6. Financial Overview

---

7. Summary Conclusion

Relay Therapeutics' potential moat lies entirely in the differentiation and productivity of its Dynamo drug discovery platform and the clinical promise of its mutant-selective PI3K-alpha inhibitor RLY-2608, with no approved products yet to validate that promise commercially. The central forward risk is binary clinical trial outcome risk combined with the capital intensity typical of clinical-stage biotechnology, meaning Relay's trajectory depends almost entirely on near-term trial readouts and its ability to fund development through to potential approval.